Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Agenus ( (AGEN) ) is now available.
On January 15, 2026, Agenus closed a $141 million strategic collaboration with Zydus Lifesciences that combines the $75 million sale of its Emeryville and Berkeley, California biologics manufacturing operations, a $16 million equity investment for roughly 2.1 million Agenus shares at $7.50 each, and up to $50 million in contingent milestone payments tied to future BOT+BAL production orders. The transaction, which constitutes a significant business disposition for Agenus, grants Zydus exclusive rights to develop and commercialize botensilimab and balstilimab in India and Sri Lanka in return for a 5% royalty on net sales, while securing committed long-term U.S. manufacturing capacity at the divested facilities to support Agenus’ Phase 3 BOT+BAL program, global access initiatives, and prospective commercialization, thereby strengthening its balance sheet and positioning the company to advance its late-stage immunotherapy strategy in microsatellite-stable colorectal cancer.
The most recent analyst rating on (AGEN) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Agenus stock, see the AGEN Stock Forecast page.
Spark’s Take on AGEN Stock
According to Spark, TipRanks’ AI Analyst, AGEN is a Neutral.
The score is primarily pressured by weak financial performance (losses, negative equity, and negative cash flows). Technicals are supportive in trend terms but show overbought conditions and high volatility, while valuation remains constrained by unprofitable earnings and no dividend support.
To see Spark’s full report on AGEN stock, click here.
More about Agenus
Agenus Inc., headquartered in Lexington, Massachusetts, is a clinical-stage immuno-oncology company focused on cancer treatments, with a pipeline built around antibody therapeutics, adoptive cell therapies through its affiliate MiNK Therapeutics, and vaccine adjuvants. The company maintains end-to-end capabilities spanning research, discovery, clinical and commercial cGMP manufacturing, and global clinical operations, and is developing its botensilimab (BOT) and balstilimab (BAL) immunotherapy combination for difficult-to-treat solid tumors such as microsatellite-stable colorectal cancer.
Average Trading Volume: 629,609
Technical Sentiment Signal: Hold
Current Market Cap: $159.2M
For detailed information about AGEN stock, go to TipRanks’ Stock Analysis page.